{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:12:46Z","timestamp":1780582366720,"version":"3.54.1"},"reference-count":23,"publisher":"Galenos Yayinevi","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Turkiye Parazitol Derg"],"published-print":{"date-parts":[[2022,5,23]]},"DOI":"10.4274\/tpd.galenos.2022.85856","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T08:47:28Z","timestamp":1653295648000},"page":"97-101","source":"Crossref","is-referenced-by-count":2,"title":["Investigation of <i>in vitro<\/i> Efficacy of Miltefosine on Chronic Cutaneous Leishmaniasis"],"prefix":"10.4274","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1799-2539","authenticated-orcid":false,"given":"Varol","family":"Tunal\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8845-1433","authenticated-orcid":false,"given":"Mehmet","family":"Harman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3860-0146","authenticated-orcid":false,"given":"\u0130brahim","family":"\u00c7avu\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9645-7085","authenticated-orcid":false,"given":"Or\u00e7un","family":"Zorbozan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3613-8741","authenticated-orcid":false,"given":"Ahmet","family":"\u00d6zbilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4517-3223","authenticated-orcid":false,"given":"Nevin","family":"Turgay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2811","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"121","DOI":"10.5152\/tpd.2012.29","article-title":"[Cutaneous leishmaniasis in Turkey]","volume":"36","author":"G\u00fcrel","year":"2012","unstructured":"1. G\u00fcrel MS, Ye\u015filova Y, Olgen MK, Ozbel Y. [Cutaneous leishmaniasis in Turkey]. Turkiye Parazitol Derg 2012; 36: 121-9.","journal-title":"Turkiye Parazitol Derg"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/j.1468-3083.2011.04266.x","article-title":"Chronic cutaneous leishmaniasis, a great mimicker with various clinical presentations: 12 years experience from Aleppo","volume":"26","author":"Douba","year":"2012","unstructured":"2. Douba MD, Abbas O, Wali A, Nassany J, Aouf A, Tibbi MS, et al. Chronic cutaneous leishmaniasis, a great mimicker with various clinical presentations: 12 years experience from Aleppo. J Eur Acad Dermatol Venereol 2012; 26: 1224-9.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS ONE 2017; 12: e0184777.","DOI":"10.1371\/journal.pone.0184777"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Vanaerschot M, Dumetz F, Roy S, Ponte-Sucre A, Arevalo J, Dujardin JC. Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? Expert Rev Anti Infect Ther 2014; 12: 937-46.","DOI":"10.1586\/14787210.2014.916614"},{"key":"ref4","unstructured":"5. Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007; 3: 733-40."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/tmi.12698","article-title":"Leishmaniasis in Turkey: first clinical isolation of Leishmania major from 18 autochthonous cases of cutaneous leishmaniasis in four geographical regions","volume":"21","author":"\u00d6zbilgin","year":"2016","unstructured":"6. \u00d6zbilgin A, \u00c7ulha G, Uzun S, Harman M, Topal SG, Okudan F, et al. Leishmaniasis in Turkey: first clinical isolation of Leishmania major from 18 autochthonous cases of cutaneous leishmaniasis in four geographical regions. Trop Med Int Heal 2016; 21: 783-91.","journal-title":"Trop Med Int Heal"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Toz SO, Culha G, Zeyrek FY, Ertabaklar H, Alkan MZ, Vardarl\u0131 AT, et al. A real-time ITS1-PCR based method in the diagnosis and species \u0131dentification of Leishmania parasite from human and dog clinical samples in Turkey. PLoS Negl Trop Dis 2013; 7: e2205.","DOI":"10.1371\/journal.pntd.0002205"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.31196\/huvfd.325794","article-title":"In Vitro Sitotoksisite Testleri","volume":"6","author":"Tokur","year":"2017","unstructured":"8. Tokur O, Aksoy A. In Vitro Sitotoksisite Testleri. Harran \u00dcniv Vet Fak Derg 2017; 6: 112-8.","journal-title":"Harran \u00dcniv Vet Fak Derg"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.mimet.2003.08.013","article-title":"Hydrosoluble formazan XTT: its application to natural products drug discovery for Leishmania","volume":"55","author":"Williams","year":"2003","unstructured":"9. Williams C, Espinosa OA, Montenegro H, Cubilla L, Capson TL, Ortega-Barr\u00eda E, et al. Hydrosoluble formazan XTT: its application to natural products drug discovery for Leishmania. J Microbiol Methods 2003; 55: 813-6.","journal-title":"J Microbiol Methods"},{"key":"ref9","unstructured":"10. Motulsky HJ. No Title [Internet]. GraphPad Statistics Guide. [cited 2020 Apr 29]. Available from: http:\/\/www.graphpad.com\/guides\/prism\/7\/statistics\/index.htm"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, L\u00f3pez-V\u00e9lez R, Garc\u00eda-Hern\u00e1ndez R, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge PLoS Negl Trop Dis 2017; 11: e0006052.","DOI":"10.1371\/journal.pntd.0006052"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2174\/156802606776743165","article-title":"Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target \u0131dentification and design of antileishmanial modulators","volume":"6","author":"Loiseau","year":"2006","unstructured":"12. Loiseau P, Bories C. Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target \u0131dentification and design of antileishmanial modulators. Curr Top Med Chem 2006; 6: 539-50.","journal-title":"Curr Top Med Chem"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1128\/CMR.19.1.111-126.2006","article-title":"Drug resistance in leishmaniasis","volume":"19","author":"Croft","year":"2006","unstructured":"13. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 111-26.","journal-title":"Clin Microbiol Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective","volume":"5","author":"Singh","year":"2016","unstructured":"14. Singh OP, Singh B, Chakravarty J, Sundar S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty 2016; 5: 19.","journal-title":"Infect Dis Poverty"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1017\/S0031182016002523","article-title":"Chemotherapy of leishmaniasis: present challenges","volume":"145","author":"Uliana","year":"2018","unstructured":"15. Uliana SRB, Trinconi CT, Coelho AC. Chemotherapy of leishmaniasis: present challenges. Parasitology 2018; 145: 464-80.","journal-title":"Parasitology"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis 2017; 11: e0005635.","DOI":"10.1371\/journal.pntd.0005635"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63: e202-64.","DOI":"10.1093\/cid\/ciw670"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1128\/AAC.45.6.1872-1875.2001","article-title":"Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice","volume":"45","author":"Escobar","year":"2001","unstructured":"18. Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 2001; 45: 1872-5.","journal-title":"Antimicrob Agents Chemother"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1086\/425359","article-title":"Oral miltefosine for Leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection","volume":"39","author":"Sindermann","year":"2004","unstructured":"19. Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for Leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39: 1520-3.","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Dorlo TPC, van Thiel PPAM, Schoone GJ, Stienstra Y, van Vugt M, Beijnen JH, et al. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Negl Trop Dis 2011; 5: e1436.","DOI":"10.1371\/journal.pntd.0001436"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis","volume":"38","author":"Soto","year":"2004","unstructured":"21. Soto J, Arana BA, Tolado J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38: 1266-72.","journal-title":"Clin Infect Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1155\/2008\/802710","article-title":"Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan","volume":"19","author":"Keynan","year":"2008","unstructured":"22. Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, Rubinstein E. Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med 2008; 19: 394-6.","journal-title":"Can J Infect Dis Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1179\/136485909X398177","article-title":"Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica","volume":"103","author":"Killingley","year":"2009","unstructured":"23. Killingley B, Lamb LEM, Davidson RN. Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica. Ann Trop Med Parasitol 2009; 103: 171-5.","journal-title":"Ann Trop Med Parasitol"}],"container-title":["Turkish Journal of Parasitology"],"original-title":[],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T13:06:00Z","timestamp":1717679160000},"score":1,"resource":{"primary":{"URL":"https:\/\/turkiyeparazitolderg.org\/articles\/doi\/tpd.galenos.2022.85856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,5,23]]},"published-print":{"date-parts":[[2022,5,23]]}},"URL":"https:\/\/doi.org\/10.4274\/tpd.galenos.2022.85856","relation":{},"ISSN":["1300-6320","2146-3077"],"issn-type":[{"value":"1300-6320","type":"print"},{"value":"2146-3077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]}}}